Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kathryn Gold
With
Pfizer
This is an open-label phase I trial with a 3+3 dose escalation design. All patients will receive avelumab, cetuximab, and palbociclib. This study will enroll patients with head and neck squamous cell carcinoma not amenable to curative intent therapy.
Treatment will be administered in 28 day cycles with a pre-defined dose escalation schedule.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically proven squamous cell carcinoma of the head and neck not amenable to curative intent therapy.
Presence of measurable tumor lesions per RECIST criteria v1.1
Life expectancy greater than 12 weeks.
Adequate hematologic, hepatic, and renal function
Negative serum or urine pregnancy test for women of child bearing potential
You may not be if
Prior therapy with an EGFR inhibitor or PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting
Uncontrolled central nervous system metastases (stable metastases permitted)
Chemotherapy 28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment.
History of other malignancies,
Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of \>10 mg/day of prednisone or equivalent)
Prior organ transplantation
Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).